Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
October 2012, Vol 3, No 7
October 2012, Vol 3, No 7
Two Genetic Signatures Can Help Identify Patients with Aggressive Prostate Cancer
Value Propositions
,
Value Peer-spectives
October 2012, Vol 3, No 7
The search for better diagnostic tools for prostate cancer continues, with current test modalities leaving much room for improvement.
Read Article
Novel Best Test to Guide Therapy in Children with Acute Myeloid Leukemia
Value Propositions
,
Value Peer-spectives
October 2012, Vol 3, No 7
Early treatment response is a strong predictor of long-term outcomes in children with acute myeloid leukemia (AML); it can further help to determine whether an aggressive treatment approach is needed.
Read Article
New Payer-Oncologist Collaboration to Curb Cancer Care Costs, Improve Quality, Launched in Michigan
Value Propositions
,
Value Peer-spectives
October 2012, Vol 3, No 7
In September, Cardinal Health Specialty Solutions announced the launch of a new collaboration initiative with Health Alliance Plan (HAP) and Physician Resource Management to establish an evidence-based clinical pathways program aimed at reducing the costs of cancer care while improving quality of care.
Read Article
The IOM Considers the Economics of Genome-Based Targeted Drug Development
Value Propositions
,
Value Peer-spectives
October 2012, Vol 3, No 7
The Institute of Medicine (IOM) recently held a roundtable discussion on the status of genome-based drug development.
Read Article
Ovarian Cancer Therapy Moving Toward Personalized Medicine
Value Propositions
,
Value Peer-spectives
October 2012, Vol 3, No 7
The recent discovery of 3 subtypes of high-grade serous ovarian cancer (HGSOC) by researchers at Dana-Farber Cancer Institute will soon enable oncologists to determine which of their patients with HGSOC—the most common type of ovarian cancer—are most likely to benefit from a certain class of drugs.
Read Article
More Evidence Supports the Anticancer Effect of Metformin
By
Charles Bankhead
Breast Cancer Symposium
October 2012, Vol 3, No 7
San Francisco, CA—Women with diabetes taking metformin had a significantly lower risk of breast cancer, an association that appeared to grow stronger with increasing duration of follow-up, results of a recent meta-analysis showed.
Read Article
An Underappreciated Cause of Cancer Death: Disparities in Treatment
By
Caroline Helwick
Breast Cancer Symposium
October 2012, Vol 3, No 7
San Francisco, CA—When cancer treatment is equal among patients, the outcomes are equal as well, “but there is not equal treatment” within the US population with cancer, according to Otis W. Brawley, MD, Chief Medical and Scientific Officer of the American Cancer Society, and Professor of Hematology, Medical Oncology, Medicine, and Epidemiology at Emory University, Atlanta.
Read Article
Fewer Women Undergo Mammography since Recent Task Force Recommendations
By
Charles Bankhead
Breast Cancer Symposium
October 2012, Vol 3, No 7
San Francisco, CA—Within weeks of a government-backed recommendation against routine screening mammography in women aged <50 years, the screening rate had fallen below historic levels and subsequently has remained lower than the baseline rate, a group of researchers reported.
Read Article
Is Personalized Cancer Care Affordable?
By
Caroline Helwick
Personalized Medicine
October 2012, Vol 3, No 7
Vienna, Austria—“Is personalized cancer care affordable?” asked Richard Sullivan, MD, PhD, Director of Kings Health Partners Institute of Cancer Policy and Global Health in the United Kingdom, in an invited presentation at the 2012 European Society for Medical Oncology Congress.
Read Article
ESMO Theme: Personalized (“Precision”) Oncology Care Marches Forward
By
Caroline Helwick
Personalized Medicine
October 2012, Vol 3, No 7
Vienna, Austria—“One of our themes at the 2012 ESMO Congress is personalized oncology,” European Society for Medical Oncology (ESMO) President Martine J. Piccart-Gebhart, MD, PhD, Professor of Oncology at the Université Libre de Bruxelles and Director of the Medicine Department at Jules Bordet Institute, Brussels, Belgium, said at a press briefing at the meeting.
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma